The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1
Open accessAbstract
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive. A parallel screening strategy was applied to test candidates from a series of diarylpyrimidines against wild-type and resistant HIV strains carrying clinically relevant mutations. Serum protein binding and metabolic stability were addressed early in the selection process. The emerging clinical candidate, TMC125, was highly active against wild-type HIV-1 (50% effective concentration [EC 50 ] = 1.4 to 4.8 nM) and showed some activity against HIV-2 (EC 50 = 3.5 μM). TMC125 also inhibited a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. Incubation of TMC125 with human liver microsomal fractions suggested good metabolic stability (15% decrease in drug concentration and 7% decrease in antiviral activity after 120 min). Although TMC125 is highly protein bound, its antiviral effect was not reduced by the presence of 45 mg of human serum albumin/ml, 1 mg of α 1 -acid glycoprotein/ml, or 50% human serum. In an initial screen for activity against a panel of 25 viruses carrying single and double reverse transcriptase amino acid substitutions associated with NNRTI resistance, the EC 50 of TMC125 was <5 nM for 19 viruses, including the double mutants K101E+K103N and K103N+Y181C. TMC125 also retained activity (EC 50 < 100 nM) against 97% of 1,081 recent clinically derived recombinant viruses resistant to at least one of the currently marketed NNRTIs. TMC125 is a potent next generation NNRTI, with the potential for use in individuals infected with NNRTI-resistant virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Self-citationGenetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes
Delwart, E., Shpaer, E., Louwagie, J., McCutchan, F., Grez, M., Rubsamen-Waigmann, H., & Mullins, J. (1993) · Science · doi:10.1126/science.8235655 · Cited by 757
Das, K., Clark, Lewi, P. J., Heeres, J., de Jonge, M. R., Koymans, L. M. H., Vinkers, H. M., Daeyaert, F., Ludovici, D. W., Kukla, M. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030558s · Cited by 514
Self-citationHertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.269 · Cited by 389
Self-citationBacheler, L. T., Jeffrey, S., Hanna, G. J., D’Aquila, R. T., Wallace, L., Logue, K. A., Cordova, B. C., Hertogs, K., Larder, B. A., Buckery, R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.4999-5008.2001 · Cited by 234
Dual-attribute continuous monitoring of cell proliferation/cytotoxicity.
Fields, R. D., & Lancaster, M. V. (1993) · PubMed · Cited by 215
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M., & Henfrey, R. D. (1993) · Nature · doi:10.1038/365671a0 · Cited by 198
Travel and the spread of HIV-1 genetic variants
Perrin, L., Kaiser, L., & Yerly, S. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00484-5 · Cited by 194
Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues
Ludovici, D. W., De Corte, B. L., Kukla, M. J., Ye, H., Ho, C. Y., Lichtenstein, M. A., Kavash, R. W., Andries, K., de Béthune, M.-P., Azijn, H., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00412-7 · Cited by 185
Self-citation
Cited by
Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61047-2 · Cited by 517
Self-citationde Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., Towner, W., Trottier, B., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61048-4 · Cited by 392
Self-citationAzijn, H., Tirry, I., Vingerhoets, J., de Béthune, M.-P., Kraus, G., Boven, K., Jochmans, D., Van Craenenbroeck, E., Picchio, G., & Rimsky, L. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00986-09 · Cited by 293
Self-citationHIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
Metadata
- Authors
- Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., & de Béthune, M.-P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-12
- Volume
- 48
- Issue
- 12
- Pages
- 4680-4686
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2172130850
- Cited by
- 322
- References
- 20
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1. https://app.cochat.ai/papers/10.1128/aac.48.12.4680-4686.2004
- The paper
- Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., & de Béthune, M.-P. (2004). TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.48.12.4680-4686.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.